USEUROPEAFRICAASIA 中文雙語Fran?ais
    China
    Home / China / Innovation

    Chinese scientists give big boost to cancer-killing virus

    Xinhua | Updated: 2017-08-24 14:41

    Chinese scientists have found a compound that helped a tumor-targeting virus kill liver cancer more effectively while sparing healthy cells, offering new hope for treating the world's second most common cancer killer, according to a study published Wednesday.

    A therapy using viruses that selectively kill cancer cells, dubbed oncolytic viruses, is rapidly progressing through clinical evaluation, but the therapeutic efficacy in humans has been less than expected from preclinical studies, according to the study published in the U.S. journal Science Translational Medicine.

    Oncolytic virotherapy involving M1 virus, a mosquito-borne pathogen that predominantly causes mild illness in horses, is believed to be a potentially attractive strategy for the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer.

    In order to boost the virus's antitumor effects, Professor Guangmei Yan of Sun Yat-sen University in China and colleagues screened 350 small molecules to identify compounds that can enhance viral killing of cultured HCC cells.

    The researchers found that Eeyarestatin I, an inhibitor of the protein VCP, which has been linked to causing malignancy, as the strongest sensitizer for M1 virus, as it increased the potency of the virus by as much as 3,600-fold against the HCC cells.

    The dual regimen had no effect on non-cancerous cells, they said.

    In multiple mouse models of HCC, M1 together with Eeyarestatin I were found to shrink tumors and significantly prolong survival.

    The researchers further demonstrated that the duo was safe and well-tolerated in monkeys.

    "We can describe the M1 oncolytic virus as a guided missile that automatically targets tumor cells, and the addition of the VCP inhibitor is just like binding the missile to powerful explosives with the ability of auto-selection," Yan explained to Xinhua.

    "The outcome is self-evident with such a strong combination," he said.

    Yan said they plan to submit a clinical trial application for the combination therapy strategy in 2018.

    "Hepatocellular carcinoma is the second leading cause of cancer-related death in men and claims more than 700,000 lives per year worldwide," their paper wrote. "Our study identifies combined VCP inhibition and oncolytic virus as a potential treatment for HCC and demonstrates promising therapeutic potential."

    Editor's picks
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
     
    台湾无码一区二区| 亚洲一区二区中文| 乱人伦人妻中文字幕无码| 无码av免费一区二区三区试看| 日韩免费在线中文字幕| 日韩免费a级毛片无码a∨| 亚洲精品高清无码视频| 国产精品中文字幕在线观看| 免费a级毛片无码| 精品无码久久久久国产| 2014AV天堂无码一区| 人妻精品久久久久中文字幕 | 国产AV无码专区亚洲AWWW| 国产乱码精品一区二区三区中文 | 亚洲精品无码你懂的网站| 久久无码人妻一区二区三区午夜| 免费看无码特级毛片| 中文字幕你懂的| 天堂中文在线最新版| 亚洲一区二区三区无码影院| 久久精品无码专区免费 | 精品深夜AV无码一区二区| 亚洲gv猛男gv无码男同短文| 中文字幕精品无码久久久久久3D日动漫| 精品久久久无码中文字幕天天| 精品久久久久久无码人妻热| 国产在线无码视频一区二区三区| 亚洲成a人片在线观看无码 | 亚洲AV无码一区二区二三区软件| 在线亚洲欧美中文精品| 无码av中文一二三区| 中文成人无码精品久久久不卡| 久久精品99无色码中文字幕| 中文字幕日韩一区| 亚洲精品欧美二区三区中文字幕| 日本久久中文字幕| 欧洲精品无码一区二区三区在线播放| 最近更新中文字幕第一页| 欧美一级一区二区中文字幕 | 中文字幕免费观看| 91中文在线观看|